Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famciclovir 1500 mg single-dose safety and pharmacokinetics in adolescents with recurrent herpes labialis
2015-004443-40Phase 2
- Sponsor
- Novartis
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of famciclovir in herpes labialis, sponsored by Novartis. Primary endpoint: Safety and tolerability.
02
Drugs
famciclovir
03
Conditions
herpes labialis
Beyond the preview
Go deeper on 2015-004443-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004443-40.